FDA Floats Oncology Authorization Shake-Up, Pitching ‘One-Trial’ Model for Accelerated and Full Approval

In draft guidance, the FDA outlined plans to move away from single-arm studies and instead favor randomized controlled trials that can potentially serve as the basis for both accelerated and full approval.